Evidence map›Paper›PMID 42630043›Full record

ArticleCancer medicine2026

A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer.

Shoko Tabara, Yutaka Suehiro, Harumi Suehiro, Ukyo Shinagawa, Kaori Hamamoto, Takanori Tsuyama, Shuhei Shinoda, Shigeyuki Suenaga, Yuki Kunimune, Ikuei Fujii and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shoko TabaraDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Yutaka SuehiroDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0000-0002-8822-0053
Harumi SuehiroDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Ukyo ShinagawaDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Kaori HamamotoDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Takanori TsuyamaDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Shuhei ShinodaDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0000-0002-4128-2177
Shigeyuki SuenagaDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0000-0003-3726-5961
Yuki KunimuneDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0009-0008-3688-4051
Ikuei FujiiDepartment of Health Screening, Ajisu Kyoritsu Hospital, Yamaguchi, Japan.
Chieko SuzukiDepartment of Internal Medicine, Ajisu Kyoritsu Hospital, Yamaguchi, Japan.ORCID https://orcid.org/0000-0002-1362-9348
Shingo HigakiDepartment of Gastroenterology, St. Hill Hospital, Ube, Japan.
Taro TakamiDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0000-0002-6689-4989
Takahiro YamasakiDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0000-0002-9793-0399

Funding

JSPS KAKENHI 24K11132
6 · The paper itself

Abstract

There are no reliable screening tests for pancreatic ductal adenocarcinoma (PDAC). We performed this study to address this issue. Using 206 serum samples from 95 healthy subjects and 111 patients with PDAC, we developed the novel ACAm-S index, which consists of age, CA19-9, and methylated somatostatin. The ACAm-S index showed a sensitivity of 91.0% (101/111) for all stages of PDAC and a specificity of 94.7% (90/95). Notably, its sensitivity was high at 85.4% (35/41), even for Stage I PDAC. The ACAm-S index may have potential as a blood-based screening tool for early-stage PDAC in the general population.

Indexed as

Biomarkers, TumorCA-19-9 AntigenCarcinoma, Pancreatic DuctalEarly Detection of CancerPancreatic NeoplasmsSomatostatinAdultAgedAge FactorsFemaleHumansMaleMiddle AgedNeoplasm StagingBiomarkers, TumorCA-19-9 AntigenSomatostatincarbohydrate antigen 19‐9liquid biopsymethylated somatostatinpancreatic ductal adenocarcinoma

Identifiers

PMID42630043
PMCPMC13498898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.